文献速递肿瘤 PET/CT

基线18F-FDG PET/CT代谢肿瘤体积在NCCN-IPI基础上对弥漫大B细胞淋巴瘤的预后价值

Prognostic value of metabolic tumour volume on baseline 18F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-04-02

该回顾性研究纳入103例初治弥漫大B细胞淋巴瘤患者,评估基线18F-FDG PET/CT定量代谢参数(以SUV≥2.5为阈值计算总代谢肿瘤体积TMTV)在NCCN-IPI之外的预后价值。中位随访34个月,TMTV是PFS和OS的独立预测因素,且能在高危NCCN-IPI(≥4)患者中进一步分层;低危NCCN-IPI(<4)患者无论TMTV如何预后均良好。

要点

  • TMTV以249 cm3为界,低TMTV者3年PFS 83%、OS 92%,高TMTV者分别为41%和57%。
  • 多因素分析显示TMTV与NCCN-IPI均为PFS和OS的独立预测因素。
  • 在高危NCCN-IPI(≥4)患者中,TMTV可进一步区分预后显著不同的两组。

核心结论

  • 治疗前TMTV是DLBCL患者生存的独立预测因素,并在高危NCCN-IPI患者中具有附加预后价值。
  • 基线TMTV与NCCN-IPI联合可能改善预后判断,并有助于指导强化治疗和临床试验决策,尤其在高危NCCN-IPI的DLBCL患者中。

研究设计与样本

  • 回顾性纳入103例连续DLBCL患者,均有基线FDG PET/CT。
  • 以SUV≥2.5为阈值计算总代谢肿瘤体积(TMTV)等定量代谢参数,用ROC曲线确定最佳截断值。
  • 采用Cox回归分析变量与生存的关系,Kaplan-Meier曲线和log-rank检验比较生存率。

主要发现

  • 中位随访34个月;低TMTV(<249 cm3)患者3年PFS率83%、OS率92%,高TMTV(≥249 cm3)患者分别为41%和57%。
  • 单因素分析中,高TMTV和NCCN-IPI≥4均与较差的PFS和OS相关(所有P<0.0001),高总病灶糖酵解亦相关(P=0.004和P=0.005)。
  • 多因素分析中,TMTV和NCCN-IPI是PFS的独立预测因素(HR 3.11,95%CI 1.37-7.07,P=0.007;HR 3.42,95%CI 1.36-8.59,P=0.009)及OS的独立预测因素(HR 3.41,95%CI 1.24-9.38,P=0.017;HR 5.06,95%CI 1.46-17.60,P=0.014)。
  • 在高危NCCN-IPI≥4患者(n=62)中,低TMTV者(n=16)3年PFS率75%、OS率88%,高TMTV者3年PFS率32%、OS率47%(χ2=7.92,P=0.005;χ2=8.26,P=0.004)。
  • 低危NCCN-IPI<4患者(n=41)无论TMTV如何,3年PFS率85%、OS率95%。

关键数值与推荐

  • TMTV计算以SUV≥2.5为阈值,最佳截断值为249 cm3。
  • 高危NCCN-IPI定义为≥4,低危定义为<4。

临床怎么用

  • 对DLBCL患者,基线18F-FDG PET/CT除常规评估外,可定量计算TMTV以辅助预后分层。
  • 在高危NCCN-IPI(≥4)患者中,结合TMTV可识别预后更差亚组,可能有助于强化治疗或临床试验决策。
  • 低危NCCN-IPI(<4)患者即使TMTV高,预后仍较好,治疗决策需综合考量。

局限性

  • 回顾性研究,样本量103例,可能存在选择偏倚。
  • TMTV截断值249 cm3基于本队列ROC分析得出,外推需验证。
  • 单中心研究,结果需多中心前瞻性研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to determine the prognostic value of metabolic volumetric parameters as a quantitative index on pre-treatment 18F-FDG PET/CT in addition to the National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) in patients with diffuse large B-cell lymphoma (DLBCL). METHODS: A total of 103 consecutive patients with DLBCL and baseline FDG PET/CT were retrospectively evaluated. Quantitative metabolic parameters, including total metabolic tumour volume (TMTV) using a standardized uptake value (SUV) of ≥2.5 as the threshold, were estimated. Receiver operating characteristic curve analysis was used to determine the optimal cut-off values for the metabolic parameters. The relationships between study variables and patient survival were tested using Cox regression analysis. Patient survival rates were derived from Kaplan-Meier curves and compared using the log-rank test. RESULTS: Median follow-up was 34 months. In patients with a low TMTV (<249 cm3), the 3-year progression free survival (PFS) rate was 83% and the overall survival (OS) rate was 92%, in contrast to 41% and 57%, respectively, in those with a high TMTV (≥249 cm3). In univariate analysis, a high TMTV and NCCN-IPI ≥4 were associated with inferior PFS and OS (P < 0.0001 for all), as was a high total lesion glycolysis (P = 0.004 and P = 0.005, respectively). In multivariate analysis, TMTV and NCCN-IPI were independent predictors of PFS (hazard ratio, HR, 3.11, 95% confidence interval, CI, 1.37-7.07, P = 0.007, and HR 3.42, 95% CI 1.36-8.59, P = 0.009, respectively) and OS (HR 3.41, 95% CI 1.24-9.38, P = 0.017, and HR 5.06, 95% CI 1.46-17.60, P = 0.014, respectively). TMTV was able to separate patients with a high-risk NCCN-IPI of ≥4 (n = 62) into two groups with significantly different outcomes; patients with low TMTV (n = 16) had a 3-year PFS rate of 75% and an OS rate of 88%, while those with a high TMTV had a 3-year PFS rate of 32% and an OS rate of 47% (χ2 = 7.92, P = 0.005, and χ2 = 8.26, P = 0.004, respectively). However, regardless of TMTV, patients with a low-risk NCCN-IPI of <4 (n = 41) had excellent outcomes (3-year PFS and OS rates of 85% and 95%, respectively). CONCLUSION: Pretreatment TMTV was an independent predictor of survival in patients with DLBCL. Importantly, TMTV had an additive prognostic value in patients with a high-risk NCCN-IPI. Thus, the combination of baseline TMTV with NCCN-IPI may improve the prognostication and may be helpful guide the decision for intensive therapy and clinical trials, especially in DLBCL patients with a high-risk NCCN-IPI.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Shagera QA, Cheon GJ, Koh Y, et al. Prognostic value of metabolic tumour volume on baseline 18F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI. Eur J Nucl Med Mol Imaging. 2019. PMID: 30941463. doi:10.1007/s00259-019-04309-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。